Health Economics›Juvenile myelomonocytic leukemia›First-line therapy

First-line therapy

Juvenile myelomonocytic leukemia · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	~8.9 mo	~6	~R 175 992 PFS proxy · indirect	12

1 of 1 regimen shown